Moderna, Inc.

Equities

MRNA

US60770K1079

Real-time Estimate Cboe BZX Other stock markets 12:32:15 07/02/2026 am IST			5-day change	1st Jan Change
40.26 ^USD	-1.49%		-8.48%	+36.78%

30/01	Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating	MT
30/01	Mib Outperforms Europe Ahead of S&P, Campari Leads Gains	AN

Transcript : Moderna, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 10

Published on 05/29/2025 at 09:05 pm IST - Modified on 07/01/2025 at 09:51 pm IST

S&P Capital IQ

Presenter Speech
Courtney Breen (Analysts)

I am thrilled to be here today with Stéphane Bancel from Moderna. My name is Courtney Breen. I am the U.S. biopharma analyst here at Bernstein. Before we dive

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Moderna, Inc.

30/01	Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating	MT
30/01	Mib Outperforms Europe Ahead of S&P, Campari Leads Gains	AN
30/01	Moderna, Inc. Announces Executive and Committee Changes, Effective March 2, 2026	CI
30/01	Moderna CMO Jacqueline Miller to step down	RE
30/01	Markets Rise Amid Strong Euro and Earnings Season	AN
30/01	Recordati and Moderna Sign Global Agreement on mRNA Therapy for Rare Disease	AN
30/01	Moderna Collaborates With Recordati to Advance, Commercialize Investigational Therapy to Treat Metabolic Disorder	MT
30/01	Recordati announces collaboration with Moderna for mRNA-3927	RE
29/01	TD Cowen Adjusts Moderna Price Target to $40 From $25, Maintains Hold Rating	MT
29/01	Repertoire Immune Medicines, Eli Lilly Set Autoimmune Collaboration	DJ
29/01	Satellos Bioscience Inc. Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs	CI
28/01	Wolfe Adjusts Price Target on Moderna to $25 From $17, Maintains Underperform Rating	MT
23/01	Bernstein Adjusts Price Target on Moderna to $35 From $25, Maintains Market Perform Rating	MT
23/01	The Market's Favorite Question Right Now: Is This a Return to Normal, or Just a Pause?
23/01	Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna…
23/01	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
23/01	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
22/01	Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV	RE
22/01	Moderna is curbing investment in vaccine trials due to US backlash - Bloomberg News	RE
22/01	Moderna Curbing Vaccine Trial Investments Over Backlash From US Officials	MT
22/01	Moderna Curbing Vaccine Trial Investments Over Backlash From US Officials, Bloomberg Reports	MT
22/01	Escalate, De-Escalate, Repeat
22/01	Stocks Gain Pre-Bell Amid Trump's Greenland Tariff Reversal; Investors Await Inflation Data	MT
22/01	Greenland Detente Levitates Wall Street Pre-Bell; Asia, Europe Rally	MT
22/01	Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality	RE